Related Experiment Videos
Dinuclear alkyldiamine platinum antitumor compounds: a structure-activity relationship study.
B A Jansen1, J van der Zwan, H den Dulk
1Leiden Institute of Chemistry, Leiden University, and Molecular Genetics, Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, P.O. Box 9502, NL-2300 RA Leiden, The Netherlands.
Journal of Medicinal Chemistry
|February 15, 2001
Summary
New platinum complexes show varying effectiveness against cancer cells. While some overcome drug resistance, others are less potent, with DNA binding not directly correlating to cytotoxicity.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Research
Background:
- Platinum-based chemotherapy is a cornerstone of cancer treatment.
- Drug resistance remains a significant clinical challenge.
- Dinuclear platinum complexes offer alternative mechanisms to overcome resistance.
Purpose of the Study:
- To synthesize and evaluate novel dinuclear trans-platinum complexes.
- To compare their cytotoxicity against cisplatin-sensitive and resistant leukemia cell lines.
- To investigate the relationship between DNA binding and cytotoxic activity.
Main Methods:
- Synthesis of six dinuclear trans-platinum complexes with varying ligands (L) and alkyl chain lengths (n).
- Cytotoxicity assays using L1210 murine leukemia and cisplatin-resistant L1210/2 cell lines.
- Quantification of platinum-DNA adducts via cellular incubation and analysis.
Main Results:
- Substituted n=4 complexes were susceptible to resistance mechanisms, unlike NH3 counterparts.
- n=6 complexes exhibited comparable efficacy in both sensitive and resistant cell lines.
- Platinum-DNA binding varied, with sterically hindered 2-picoline compounds showing significantly less binding, which did not correlate with cytotoxicity.
Conclusions:
- Ligand substitution and alkyl chain length influence the activity of dinuclear platinum complexes.
- The n=6 dinuclear complexes show promise for overcoming cisplatin resistance.
- Structural characteristics of DNA adducts likely dictate differences in cytotoxic activity, not just the amount of platinum bound.